Eli Lilly and Company

Symbol: LLY.DE

XETRA

718.4

EUR

Market price today

  • 114.0975

    P/E Ratio

  • 6.5161

    PEG Ratio

  • 682.77B

    MRK Cap

  • 0.01%

    DIV Yield

Eli Lilly and Company (LLY-DE) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.80%

Operating Profit Margin

0.24%

Net Profit Margin

0.17%

Return on Assets

0.10%

Return on Equity

0.54%

Return on Capital Employed

0.19%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO:Mr. David A. Ricks
Full-time employees:43000
City:Indianapolis
Address:Lilly Corporate Center
IPO:2007-12-27
CIK:

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

General Outlook

When we look at how much money they make before expenses, they keep 0.802% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.237%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.171%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.096% return, is a testament to Eli Lilly and Company's adeptness in optimizing resource deployment. Eli Lilly and Company's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.535%. Furthermore, the proficiency of Eli Lilly and Company in capital utilization is underscored by a remarkable 0.188% return on capital employed.

Stock Prices

Eli Lilly and Company's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $723.5, while its low point bottomed out at $697.5. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Eli Lilly and Company's stock market.

Liquidity Ratios

Analyzing LLY.DE liquidity ratios reveals its financial health of the firm. The current ratio of 135.44% gauges short-term asset coverage for liabilities. The quick ratio (67.75%) assesses immediate liquidity, while the cash ratio (13.23%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio135.44%
Quick Ratio67.75%
Cash Ratio13.23%

Profitability Ratios

LLY.DE profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 21.04% underscores its earnings before tax deductions. The effective tax rate stands at 18.81%, revealing its tax efficiency. The net income per EBT, 81.19%, and the EBT per EBIT, 88.66%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 23.73%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin21.04%
Effective Tax Rate18.81%
Net Income per EBT81.19%
EBT per EBIT88.66%
EBIT per Revenue23.73%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.35, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding68
Days of Inventory Outstanding312
Operating Cycle414.13
Days of Payables Outstanding127
Cash Conversion Cycle287
Receivables Turnover3.59
Payables Turnover2.88
Inventory Turnover1.17
Fixed Asset Turnover2.64
Asset Turnover0.56

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 4.06, and free cash flow per share, -4.31, depict cash generation on a per-share basis. The cash per share value, 2.86, showcases liquidity position. A payout ratio of 0.69 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.10, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share4.06
Free Cash Flow per Share-4.31
Cash per Share2.86
Payout Ratio0.69
Operating Cash Flow Sales Ratio0.10
Free Cash Flow to Operating Cash Flow Ratio-1.06
Cash Flow Coverage Ratio0.14
Short Term Coverage Ratio2.23
Capital Expenditure Coverage Ratio0.49
Dividend Paid and Capex Coverage Ratio0.31
Dividend Payout Ratio0.01

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 40.99%, highlights its total liabilities relative to assets. With a debt-equity ratio of 2.05, we discern the balance between debt and equity financing. The long-term debt to capitalization, 65.72%, and total debt to capitalization, 67.17%, ratios shed light on its capital structure. An interest coverage of 15.15 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio40.99%
Debt Equity Ratio2.05
Long Term Debt to Capitalization65.72%
Total Debt to Capitalization67.17%
Interest Coverage15.15
Cash Flow to Debt Ratio0.14
Company Equity Multiplier4.99

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 37.91, provides a glimpse into top-line earnings distributed across each share. Net income per share, 5.82, reflects the portion of profit attributed to each share. The book value per share, 11.97, represents the net asset value distributed per share, while the tangible book value per share, -1.09, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share37.91
Net Income Per Share5.82
Book Value Per Share11.97
Tangible Book Value Per Share-1.09
Shareholders Equity Per Share11.97
Interest Debt Per Share28.56
Capex Per Share-8.21

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 19.56%, indicates top-line expansion, while the gross profit growth, 23.41%, reveals profitability trends. EBIT growth, 53.33%, and operating income growth, 53.33%, offer insights into operational profitability progression. The net income growth, -16.08%, showcases bottom-line expansion, and the EPS growth, -16.02%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth19.56%
Gross Profit Growth23.41%
EBIT Growth53.33%
Operating Income Growth53.33%
Net Income Growth-16.08%
EPS Growth-16.02%
EPS Diluted Growth-15.65%
Weighted Average Shares Growth-0.17%
Weighted Average Shares Diluted Growth-0.49%
Dividends per Share Growth15.29%
Operating Cash Flow Growth-40.15%
Free Cash Flow Growth-168.52%
10-Year Revenue Growth per Share77.28%
5-Year Revenue Growth per Share81.26%
3-Year Revenue Growth per Share40.21%
10-Year Operating CF Growth per Share-11.23%
5-Year Operating CF Growth per Share-12.37%
3-Year Operating CF Growth per Share-34.22%
10-Year Net Income Growth per Share34.31%
5-Year Net Income Growth per Share85.11%
3-Year Net Income Growth per Share-14.69%
10-Year Shareholders Equity Growth per Share-26.64%
5-Year Shareholders Equity Growth per Share25.12%
3-Year Shareholders Equity Growth per Share92.52%
10-Year Dividend per Share Growth per Share130.40%
5-Year Dividend per Share Growth per Share100.96%
3-Year Dividend per Share Growth per Share52.69%
Receivables Growth32.45%
Inventory Growth33.95%
Asset Growth29.33%
Book Value per Share Growth1.32%
Debt Growth55.34%
R&D Expense Growth29.52%
SGA Expenses Growth7.78%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 545,987,400,724.16, captures the company's total value, considering both debt and equity. Income quality, 0.81, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.20, gauges operational efficiency, while the research and development to revenue, 27.29%, highlights investment in innovation. The ratio of intangibles to total assets, 18.51%, indicates the value of non-physical assets, and capex to operating cash flow, -174.34%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value545,987,400,724.16
Income Quality0.81
Sales General and Administrative to Revenue0.20
Research and Development to Revenue27.29%
Intangibles to Total Assets18.51%
Capex to Operating Cash Flow-174.34%
Capex to Revenue-21.66%
Capex to Depreciation-484.00%
Stock-Based Compensation to Revenue1.84%
Graham Number39.59
Return on Tangible Assets10.05%
Graham Net Net-43.13
Working Capital-1,566,200,000
Tangible Asset Value-982,600,000
Net Current Asset Value-27,415,600,000
Invested Capital2
Average Receivables9,947,550,000
Average Payables2,264,700,000
Average Inventory5,041,250,000
Days Sales Outstanding121
Days Payables Outstanding134
Days of Inventory On Hand298
ROIC24.27%
ROE0.49%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 54.66, and the price to book ratio, 54.66, reflect the market's valuation relative to the company's book value. The price to sales ratio, 20.48, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -188.92, and price to operating cash flows, 190.55, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio54.66
Price to Book Ratio54.66
Price to Sales Ratio20.48
Price Cash Flow Ratio190.55
Price Earnings to Growth Ratio6.52
Enterprise Value Multiple45.85
Price Fair Value54.66
Price to Operating Cash Flow Ratio190.55
Price to Free Cash Flows Ratio-188.92
Price to Tangible Book Ratio48.61
Enterprise Value to Sales16.00
Enterprise Value Over EBITDA43.84
EV to Operating Cash Flow128.77
Earnings Yield1.00%
Free Cash Flow Yield-0.60%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Eli Lilly and Company (LLY.DE) on the XETRA in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 114.097 in 2024.

What is the ticker symbol of Eli Lilly and Company stock?

The ticker symbol of Eli Lilly and Company stock is LLY.DE.

What is company IPO date?

IPO date of Eli Lilly and Company is 2007-12-27.

What is company current share price?

Current share price is 718.400 EUR.

What is stock market cap today?

The market cap of stock today is 682770952000.000.

What is PEG ratio in 2024?

The current 6.516 is 6.516 in 2024.

What is the number of employees in 2024?

In 2024 the company has 43000.